APG350

12/01/2013 - "In vivo, treatment of mice bearing Colo205-xenograft tumors with APG350 showed a dose-dependent antitumor efficacy. "
12/01/2013 - "In vitro, APG350 is a potent inducer of apoptosis on human tumor cell lines and primary tumor cells. "
01/01/2018 - "APG350 treatment of established tumors (palliative treatment) significantly reduced tumor burden. "
01/01/2018 - "To study the effects of APG350 on PDAC cells in vivo, we applied two different orthotopic xenotransplantation mouse models, with and without primary tumor resection, representing adjuvant and palliative treatment regimes, respectively. "
01/01/2018 - "Moreover, our results suggest that combining APG350 with Navitoclax might be a succesfull strategy for cancers harboring mitochondrial apoptosis resistance."

01/01/2018 - "Here we report on preclinical in vitro and in vivo studies testing the activity of APG350 on pancreatic ductal adenocarcinoma (PDAC) cells. "

01/01/2018 - "The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells."

01/01/2018 - "Upon primary tumor resection and subsequent APG350 treatment (adjuvant therapy), APG350 limited recurrent tumor growth and metastases. "